Provided by Tiger Trade Technology Pte. Ltd.

FUSEN PHARM

0.800
-0.105-11.60%
Volume:362.00K
Turnover:288.85K
Market Cap:591.20M
PE:-50.31
High:0.870
Open:0.830
Low:0.780
Close:0.905
52wk High:1.750
52wk Low:0.320
Shares:739.00M
HK Float Shares:739.00M
Volume Ratio:1.26
T/O Rate:0.05%
Dividend:- -
Dividend Rate:- -
EPS(LYR):-0.016
ROE:-3.25%
ROA:-0.46%
PB:1.41
PE(LYR):-50.31
PS:1.85

Loading ...

BRIEF-Fusen Pharmaceutical Says Piracetam Injection Approved For Marketing By NMPA

Reuters
·
Jun 16

Fusen Pharma's Piracetam Injection Receives Market Approval in China

Stock News
·
Jun 16

Fusen Pharma says China NMPA approves piracetam injection for market launch

Reuters
·
Jun 16

Fusen Pharmaceutical Co - Piracetam Injection Approved for Memory Impairment and Cerebral Dysfunction

THOMSON REUTERS
·
Jun 16

Key Corporate Developments and Share Repurchases Highlight Hong Kong Market Activity

Stock News
·
Jun 09

Fusen Pharmaceutical Says Agomelatine Tablets Approved For Marketing In China By NMPA

Reuters
·
Jun 08

FUSEN PHARM's Agomelatine Tablet Receives Market Approval in China

Stock News
·
Jun 08

Fusen Pharmaceutical Co - Agomelatine Tablets Approved for Marketing in China by Nmpa for Depression

THOMSON REUTERS
·
Jun 08

FUSEN PHARM Posts May 2026 Monthly Return: No Share Capital Changes, 16 Million Options Outstanding

Bulletin Express
·
Jun 01

Fusen Pharma Units Gets China Nod to Market Post-Operative Pain Drug

MT Newswires Live
·
May 11

Fusen Pharm Secures NMPA Approval for Lornoxicam Injection to Address Post-Operative Pain

Bulletin Express
·
May 11

Fusen Pharmaceutical - Unit's Lornoxicam for Injection Got Approval for Marketing From China's Nmpa

THOMSON REUTERS
·
May 11

Fusen Pharma says China approves lornoxicam injection for marketing

Reuters
·
May 11

FUSEN PHARM 2025年度业绩现显著改善:收入降至2.73亿元,亏损大幅收窄

Bulletin Express
·
Apr 30

Fusen Pharmaceutical Schedules 29 May 2026 AGM; Seeks 20% Issuance and 10% Buy-back Mandates

Bulletin Express
·
Apr 30

Fusen Pharmaceutical to Seek 20% Issuance Mandate and 10% Buyback Authority at 29 May 2026 AGM

Bulletin Express
·
Apr 30

Fusen Pharmaceutical announces annual general meeting notice

Reuters
·
Apr 30

Fusen Pharmaceutical publishes 2025 annual report

Reuters
·
Apr 30

BRIEF-Fusen Pharmaceutical Says Dydrogesterone Tablet Receives Marketing Approval From PRC NMPA

Reuters
·
Apr 27

Fusen Pharmaceutical Unit Gets Marketing Nod for Progesterone Deficiency Drug in China

MT Newswires Live
·
Apr 27